Jacobio Pharmaceuticals Group Co., Ltd. ((HK:1167)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jacobio Pharmaceuticals Group Co., Ltd. is conducting a clinical study titled ‘A Multicenter, Open Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration.’ The study aims to assess the safety and effectiveness of JAB-23E73, a promising drug for treating advanced solid tumors with KRAS mutations, which could significantly impact cancer treatment.
The study focuses on JAB-23E73, an orally administered drug, tested in two phases: Phase 1 Dose Escalation and Phase IIa Dose Expansion. The drug is designed to target and treat tumors with specific genetic alterations.
The study is interventional, non-randomized, and follows a sequential intervention model without masking. Its primary purpose is treatment-focused, aiming to establish the drug’s safety and preliminary efficacy.
Key dates for the study include its start date on April 28, 2025, which marks the beginning of patient recruitment. The primary completion and estimated completion dates are yet to be announced, but the last update was also on April 28, 2025, indicating the study’s active status.
This study update could influence Jacobio Pharmaceuticals’ stock performance positively, as successful results might enhance investor confidence and position the company competitively within the oncology market. The focus on KRAS mutations, a challenging target, highlights the potential for significant advancements in cancer treatment.
The study is ongoing, with further details available on the ClinicalTrials portal.